GlassScriptPhysician profile
Robert Cody Russell
NPI 1801286059
$2,507.70
in general payments reported to CMS, 2019-2025
36 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $624 · 2023: $478 · 2024: $580 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $441.48 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $278.23 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $189.75 | 2021-2024 | |
| Glaxosmithkline, LLC. | $169.85 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $155.49 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $137.57 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $106.63 | 2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $86.07 | 2023-2025 | |
| Vericel Corporation | $81.48 | 2024 | Nexobrid |
| Radius Health, INC. | $76.94 | 2024-2025 | Tymlos |
| Corcept Therapeutics | $75.04 | 2021-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.84 | 2022-2024 | Xifaxan, Trulance |
| Medtronic, INC. | $64.79 | 2025 | Symplicity G3, Minimed 780g |
| Amarin Pharma, INC. | $61.64 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $41.48 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $41.25 | 2024 | Voquezna |
| Astellas Pharma US INC | $37.66 | 2024 | Veozah |
| Amgen INC. | $36.03 | 2024-2025 | Evenity, Prolia |
| Aurinia Pharma U.S., INC. | $33.50 | 2022-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $32.21 | 2022-2023 | Purified Cortrophin Gel |
| Novo Nordisk INC | $30.77 | 2023-2024 | Ozempic, Rybelsus |
| Baxter Healthcare | $25.79 | 2022 | |
| Welch Allyn | $25.79 | 2021 | |
| Smith+Nephew, INC. | $21.84 | 2025 | Collagenase Santyl |
| Upsher-Smith Laboratories LLC | $21.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.79 | 2022 | |
| Genzyme Corporation | $20.33 | 2024 | |
| Xeris Pharmaceuticals, INC. | $18.00 | 2024 | Gvoke Hypopen |
| Kiniksa Pharmaceuticals International, Plc | $16.06 | 2024 | Arcalyst |
| Mallinckrodt Hospital Products INC. | $15.05 | 2021 | |
| Daiichi Sankyo INC. | $14.64 | 2021 | |
| Grifols USA, LLC | $14.07 | 2021 | |
| Philips North America LLC | $13.51 | 2024 | (5091) Amb Mon & Diag Und |
| Alfasigma USA, INC. | $12.41 | 2021 | |
| Recordati_rare_diseases_inc. | $12.22 | 2021 | |
| Merck Sharp & Dohme LLC | $11.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.